ML-211 is a potent and selective inhibitor of the enzyme diacylglycerol lipase-alpha (DAGL-α), which plays a crucial role in the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG). Its primary application lies in research settings, where it is used to study the physiological and pathological roles of the endocannabinoid system. By inhibiting DAGL-α, ML-211 helps researchers understand the impact of reduced 2-AG levels on processes such as neurotransmission, inflammation, and pain signaling. This makes it a valuable tool for investigating potential therapeutic targets for conditions like chronic pain, neurodegenerative diseases, and mood disorders. Additionally, ML-211 is utilized in pharmacological studies to explore the broader implications of modulating endocannabinoid signaling pathways.